Vaccinia
MONDO:0002595The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.
21 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Cancer-Killing virus trial launches for patients out of options
Disease control Recruiting nowThis Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…
Phase: PHASE1 • Sponsor: ViroMissile, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Cancer-Killing virus shows promise in tough ovarian cancer trial
Disease control Recruiting nowThis Phase 3 study tests whether a modified virus called Olvi-Vec, given with chemotherapy and bevacizumab, can help women with ovarian cancer that no longer responds to platinum drugs. About 186 participants will receive either the virus combination or standard chemotherapy. The…
Phase: PHASE3 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Experimental drug targets smallpox and monkeypox after exposure
Disease control AVAILABLEThis trial tests the drug tecovirimat in people who have been exposed to or infected with orthopox viruses, including smallpox, monkeypox, and cowpox. Participants receive oral tecovirimat to see if it can control the infection and prevent serious complications. The study include…
Sponsor: U.S. Army Medical Research and Development Command • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Cancer-Fighting virus plus chemo and immunotherapy takes on lung cancer in new trial
Disease control Recruiting nowThis study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…
Phase: PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can donor cells stop viruses after transplant?
Disease control Recruiting nowThis study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Virus injection takes on tough pancreatic cancer
Disease control Recruiting nowThis early study tests a new treatment called hV01, a virus modified to attack cancer cells and boost the immune system. It is for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to see if the virus can shrink tumors and control t…
Phase: PHASE2 • Sponsor: Hangzhou Converd Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Supercharged donor cells take on viruses after transplant
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Scientists launch major study to track viruses in healthy and immunocompromised patients
Knowledge-focused Recruiting nowThis study aims to collect samples and medical information from people of all ages who have or have been exposed to viral infections, including COVID-19 and herpes. Researchers want to understand how viruses affect healthy individuals versus those with weakened immune systems. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC